Peptide Comparison
ChonlutenvsCrystagen
Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue
Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides
At a Glance
Quick
comparison
Dose Range
Chonluten
5–10 mg
Crystagen
1–100 mcg/kg
Frequency
Chonluten
Once daily
Crystagen
Once daily
Administration
Chonluten
Sublingual (enteric-coated capsules)
Crystagen
Subcutaneous injection
Cycle Length
Chonluten
12+ weeks
Crystagen
8-12 weeks
Onset Speed
Chonluten
Gradual (3-4 weeks)
Crystagen
Gradual (3-4 weeks)
Evidence Level
Chonluten
Limited human trials
Crystagen
Limited human trials
Efficacy
Benefit
ratings
Respiratory Tissue Repair
Lung Inflammation Control
Age-Related Lung Protection
Immune Rejuvenation
Healthy Aging
Cancer Defense
Technical Data
Compound
specifications
Chonluten
Molecular Formula
C11H17N3O8
Molecular Weight
319.27 g/mol
Half-Life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure
CAS Number
75007-24-8
Crystagen
Molecular Formula
C14H21N3O8
Molecular Weight
359.3 g/mol
Half-Life
Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure
CAS Number
Not assigned (patented as immunogeroprotective peptide, US8057810B2)
Protocols
Dosing
tiers
Chonluten
Crystagen
Applications
Best
suited for
Chonluten
Respiratory health restoration in aging individuals with declining lung function
Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic bronchopulmonary conditions requiring tissue-level regenerative support
Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for lung tissue preservation in elderly populations
Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Crystagen
Restoring thymic function and immune competence in aging individuals with immune senescence
Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting immune function during and after illness recovery
Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Chonluten
Common
- Injection site reaction
- Mild fatigue
- Transient respiratory changes
- Mild headache
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
Crystagen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
Research Status
Safety
& evidence
Chonluten
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive pulmonary infections requiring immediate medical treatment
- xSevere immunosuppression without medical supervision — immunomodulatory effects may be unpredictable
Crystagen
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive autoimmune disease in flare without physician supervision
- xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens
Decision Guide
Which is
right for you?
Choose Chonluten if...
- Respiratory health restoration in aging individuals with declining lung function
- Chronic bronchopulmonary conditions requiring tissue-level regenerative support
- Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
- Geroprotective therapy for lung tissue preservation in elderly populations
Choose Crystagen if...
- Restoring thymic function and immune competence in aging individuals with immune senescence
- Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
- Supporting immune function during and after illness recovery
- Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence